Full-Time

Associate Director

Market Access Strategy, Immunology

Posted on 1/15/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops medicines for serious diseases

Biotechnology
Healthcare

Compensation Overview

$154.8k - $252.8kAnnually

Senior

Tarrytown, NY, USA

Category
Project Management
Strategy Development
Business & Strategy
Required Skills
Data Analysis
Requirements
  • Strong analytical skills
  • Ability to manage a fluid workload without compromising quality
  • Experience in cross-functional collaboration
  • Ability to innovate and influence strategic decisions
  • Knowledge of HEOR, medical, clinical, and regulatory teams
Responsibilities
  • Participate in the review, assessment and governance preparation of time sensitive requests for price change or indication expansion for products from global affiliates
  • Create and present analytics that guide leadership decisions on pricing, resourcing, and market access strategies
  • Lead market access contribution to the annual brand planning process and other strategic initiatives that grow brand value
  • Collaborate with HEOR, medical, clinical, and regulatory teams to identify the clinical and economic evidence needed to support products growing value proposition
  • Develop training resources that build internal knowledge of market access and pricing as a key commercial capability
Desired Qualifications
  • Thrives in a dynamic environment
  • Motivated to accelerate development in the commercial organization of a science-driven patient-centric global pharmaceutical company
  • Proven ability to manage a significant workload
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its development efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and licensing its technologies. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring that its products meet high safety and efficacy standards.

Company Stage

IPO

Total Funding

$684M

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Regeneron's investment in Truveta enhances its genomic data capabilities for personalized medicine.
  • The Oxular acquisition expands Regeneron's portfolio in retinal disorder treatments.
  • Dupixent's FDA review for CSU could open a new revenue stream for Regeneron.

What critics are saying

  • Class action lawsuits may lead to financial liabilities and reputational damage.
  • Investment in Truveta may not yield expected financial returns.
  • Competition from AstraZeneca and Amgen could impact Regeneron's market share.

What makes Regeneron Pharmaceuticals unique

  • Regeneron leverages proprietary technologies for innovative treatments in serious diseases.
  • The company collaborates with academic and research institutions to enhance R&D efforts.
  • Regeneron's strategic partnerships enable shared costs and profits in new treatment development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours